Will the AstraZeneca share price be boosted by positive trial results?

AstraZeneca plc (LON: AZN) reports excellent data for cancer drug Lynparza. Can this help drive the share price upwards?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shareholders of pharmaceutical giant AstraZeneca (LSE: AZN) recently got some good news in the form of trial data presented at the annual meeting of the American Society of Clinical Oncology. They also have had to contend with the emergence of a new generic competitor to one of the company’s blockbuster drugs. What does this mean for the future of AstraZeneca, and should owners be excited or worried?

Positive trial results

AstraZeneca announced that its cancer treatment Lynparza (developed in collaboration with Merck) was shown to nearly double the time without disease progression in patients with advanced pancreatic cancer. The drug, which is already approved for the treatment of ovarian and breast cancers, showed no disease progression in 34% of patients after one year (versus 15% on a placebo) and in 22% of patients after two years (versus 10% on the placebo).

This represents a major breakthrough in the study and treatment of pancreatic cancer, which has historically been one of the most aggressive forms of the disease. Moreover, it is thought that its mechanism of action could be replicated in the treatment of other cancers caused by similar mutations.

Sales of Lynparza totalled £511m in 2018, representing an increase of 118%. This is a trend that I expect will continue, as AstraZeneca continues to implement its pivot towards oncotherapy.

Competition intensifies

However, not everything has been plain sailing for the company. Competition from producers of generics and bio-similars represents a big problem for drugmakers, and AstraZeneca is no different. Just recently, Novartis launched a generic variant of AstraZeneca’s Faslodex, a treatment for hormone receptor-positive metastatic breast cancer. Sales of Faslodex totalled £812m in 2018, and represented 5% of the business’s total sales.

It has been on the US market since 2002, and has been approved in Europe since 2004, but it only recently achieved blockbuster status (annual sales of over $1bn), with total sales of almost £810bn in 2018. This surge was due to a watershed phase 3 study published in 2017 that demonstrated the drug’s effectiveness in a number of new applications. AstraZeneca has fought the introduction of the Novartis generic for several years with some success, but it appears that its time is now up.

Investor’s perspective

With a forward P/E of 21, the stock is not cheap, although a solid dividend yield of 3.7% may offset that concern. Taking a long-term view, I think that the positive trial results for Lynparza will ultimately prove to be of more importance to the stock. The Faslodex generic has been in the works for some time now, and AstraZeneca has been lucky to have retained exclusivity for so long. Meanwhile, Lynparza has the potential to really take off, and contribute meaningfully to sales growth for years.

Right now, shares of AstraZeneca trade at just under 6,000p, and have changed hands between 5,000p and 6,500p over the past 12 months. I don’t think that the trial results will have an immediate impact on that share price, but if Lynparza were to be approved for additional indications, I would expect to see a boost to AstraZeneca’s valuation. 

While the final word on approval rests with the regulators, this trial data will go a long way towards making the case for the drug. At the end of the day, there just aren’t that many effective treatments for pancreatic cancer. Expect to hear more about this treatment from AZN. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stepan Lavrouk has no position in any share mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

After crashing 50%, is now the perfect time to buy this world-class FTSE 250 share?

The worst-performing share on the FTSE 250 over the last year is also the most exciting one of all. How…

Read more »

Illustration of flames over a black background
Investing Articles

Just released: July’s higher-risk, high-reward stock recommendation [PREMIUM PICKS]

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.

Read more »

Investing Articles

Is this one of the FTSE 100’s best-value growth shares?

Looking for great-value recovery shares to buy today? Based on City forecasts, this could be one of the best that…

Read more »

Investing Articles

Will the Tesco share price hit a 10-year high in 2024?

Up from 200p less than two years ago, the Tesco share price has enjoyed impressive growth lately. Now I'm considering…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Nearing its 12-year low, this FTSE growth stock could be the bargain of the year!

Harvey Jones has happy memories of owning this FTSE 100 growth stock. Now he's wondering whether to take a trip…

Read more »

Investing Articles

BT share price: a bargain or one to avoid?

This Fool has been keeping tabs on the BT share price. Despite looking cheap, he's steering clear of the stock…

Read more »

Electric cars charging in station
Investing Articles

Where will Tesla stock be in 5 years? Here’s what the experts say

The analysts' outlook for Tesla stock in the next few years seems to be all over the place, as the…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

3 reasons why I predict UK shares will soar over the next 12 months!

Our writer believes there are plenty of reasons why UK shares will do well over the next year or so.…

Read more »